150 related articles for article (PubMed ID: 19013168)
1. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance.
Francis G; Duggan A
Gastroenterology; 2008 Dec; 135(6):2156-7. PubMed ID: 19013168
[No Abstract] [Full Text] [Related]
2. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease.
Hanauer SB
Am J Gastroenterol; 2005 Jul; 100(7):1438-9. PubMed ID: 15984961
[No Abstract] [Full Text] [Related]
3. Immunogenicity of infliximab in Crohn's disease.
Hanauer SB
N Engl J Med; 2003 May; 348(21):2155-6; author reply 2155-6. PubMed ID: 12761378
[No Abstract] [Full Text] [Related]
4. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy.
Lichtenstein GR
Am J Gastroenterol; 2005 Jul; 100(7):1433-5. PubMed ID: 15984959
[No Abstract] [Full Text] [Related]
5. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. CON: "lifetime use" is an awfully long time.
Loftus EV
Am J Gastroenterol; 2005 Jul; 100(7):1435-8. PubMed ID: 15984960
[No Abstract] [Full Text] [Related]
6. Timing infliximab therapy in pediatric Crohn's disease.
Kirschner BS; Huo D
Gastroenterology; 2007 Mar; 132(3):1167-70. PubMed ID: 17383435
[No Abstract] [Full Text] [Related]
7. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
Rutgeerts P; Diamond RH; Bala M; Olson A; Lichtenstein GR; Bao W; Patel K; Wolf DC; Safdi M; Colombel JF; Lashner B; Hanauer SB
Gastrointest Endosc; 2006 Mar; 63(3):433-42; quiz 464. PubMed ID: 16500392
[TBL] [Abstract][Full Text] [Related]
8. Guidelines for treatment with infliximab for Crohn's disease.
Hommes DW; Oldenburg B; van Bodegraven AA; van Hogezand RA; de Jong DJ; Romberg-Camps MJ; van der Woude J; Dijkstra G;
Neth J Med; 2006; 64(7):219-29. PubMed ID: 16929083
[TBL] [Abstract][Full Text] [Related]
9. Maintenance infliximab infusions forever?
Lee SD; Surawicz CM
Am J Gastroenterol; 2002 Nov; 97(11):2917-8. PubMed ID: 12425570
[No Abstract] [Full Text] [Related]
10. Mucosal healing in Crohn's disease: what you see is what you get?
Mahadevan U
Gastrointest Endosc; 2006 Mar; 63(3):443-4. PubMed ID: 16500393
[No Abstract] [Full Text] [Related]
11. Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize.
Sandborn WJ
Gastroenterology; 2003 Apr; 124(4):1140-5. PubMed ID: 12671907
[No Abstract] [Full Text] [Related]
12. The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab.
Kopylov U; Mantzaris GJ; Katsanos KH; Reenaers C; Ellul P; Rahier JF; Israeli E; Lakatos PL; Fiorino G; Cesarini M; Tsianos EV; Louis E; Ben-Horin S
Aliment Pharmacol Ther; 2011 Feb; 33(3):349-57. PubMed ID: 21118397
[TBL] [Abstract][Full Text] [Related]
13. Episodic retreatment versus scheduled maintenance therapy of crohn's disease with infliximab: not so far apart.
Sartor RB
Gastroenterology; 2004 Feb; 126(2):598-601. PubMed ID: 14762796
[No Abstract] [Full Text] [Related]
14. Infliximab treatment of postoperative ulcers in Crohn's disease: to inject or not to inject--that is the question.
Blonski W; Lichtenstein GR
Gastrointest Endosc; 2006 Mar; 63(3):493-6. PubMed ID: 16500403
[No Abstract] [Full Text] [Related]
15. Induction of pustular lesions during infliximab therapy for Crohn's disease.
Pérez-Pérez L; Caeiro JL; Fabeiro JM; Allegue F; Zulaica A
Acta Derm Venereol; 2008; 88(3):292-3. PubMed ID: 18480940
[No Abstract] [Full Text] [Related]
16. Inflammatory bowel disease and pregnancy: report of two cases treated with infliximab and a review of the literature.
Correia LM; Bonilha DQ; Ramos JD; Ambrogini O; Miszputen SJ
Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1260-4. PubMed ID: 20671559
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with infliximab and immunomodulators: is the glass half empty?
Deshpande AR; Abreu MT
Gastroenterology; 2008 Jun; 134(7):2161-3. PubMed ID: 18482585
[No Abstract] [Full Text] [Related]
18. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.
Gisbert JP; Panés J
Am J Gastroenterol; 2009 Mar; 104(3):760-7. PubMed ID: 19174781
[TBL] [Abstract][Full Text] [Related]
19. Infliximab treatment for symptomatic Crohn's disease strictures.
Pelletier AL; Kalisazan B; Wienckiewicz J; Bouarioua N; Soulé JC
Aliment Pharmacol Ther; 2009 Feb; 29(3):279-85. PubMed ID: 19035967
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease.
Abdelmalek MF; Liu C; Valentine JF
Am J Gastroenterol; 2007 Jun; 102(6):1333-4. PubMed ID: 17531027
[No Abstract] [Full Text] [Related]
[Next] [New Search]
